Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. - Hengeveld PJ; Schilperoord-Vermeulen J; van der Klift MY; Dubois JMN; Kolijn PM; Kavelaars FG; Rijken M; Dobber JA; Nasserinejad K; Kersting S; Westerweel PE; Kater AP; et al. (Blood cancer journal, 2023)